Anavex Life Sciences Corp (AVXL)

[sokol]

Responder groups may not be unusual, but I do not understand why that is a negative for Anavex stock investors, for what Anavex has done in studying responders in connection with its clinical trials, or for any drug company conducting a clinical trial.

I think the concept of precision medicine is based on determining what a patient may respond to for treatment and proceeding from there as opposed to simply applying the traditional ”cookie-cutter” medicine approach.

Here, Ariana has attempted to apply the cancer playbook to AD.

http://www.arianapharma.com/2017/12/arianas-kem-data-analysis-shows-positive-results-for-valiseek-val401-in-phase-ii-trial-for-non-small-cell-lung-cancer-nsclc-patients/

”Understanding “Super Responders” May Drive Personalized Treatment”. This his article begins by saying:

”Recent studies report that the future in health care lies in personalized medicine. Personalized medicine is a developing field of health care that takes into account individual clinical, genetic, environmental, behavioral and other factors in treating disease. This approach has been used successfully in some medical fields already, including oncology and pulmonology, specifically for cystic fibrosis. In late August 2017, personalized medicine took another step forward with the U.S. Food & Drug Administration approval of tisagenlecleucel (Kymriah®) for certain pediatric and young adult patients with acute lymphoblastic leukemia. Tisagenlecleucel is the first gene therapy approved in the U.S. that uses genetically modified cells from the patient’s own immune system, and “teaches” them to recognize, target, and kill cancerous cells.”

The latter article then goes on to state: ”To dive deeper, two researchers conducted a review and looked at what is already known about response to PAH-related medication, how clinicians identify “super responders” to these therapies and what the future might hold for personalized medicine in PAH patients. (https://www.ncbi.nlm.nih.gov/pubmed/28597766)
”Understanding “Super Responders” May Drive Personalized Treatment”’

https://phassociation.org/understanding-super-responders-may-drive-personalized-treatment/

See also: https://www.cancer.gov/about-cancer/treatment/research/exceptional-responders-initiative-qa